[{"orgOrder":0,"company":"Indapta Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Financing","leadProduct":"Cyclophosphamide","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Indapta Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"Indapta Therapeutics \/ RA Capital Management","highestDevelopmentStatusID":"7","companyTruncated":"Indapta Therapeutics \/ RA Capital Management"},{"orgOrder":0,"company":"Indapta Therapeutics","sponsor":"Multiple Myeloma Research Foundation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Indapta Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Indapta Therapeutics \/ Multiple Myeloma Research Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Indapta Therapeutics \/ Multiple Myeloma Research Foundation"},{"orgOrder":0,"company":"Indapta Therapeutics","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Collaboration","leadProduct":"IDP-023","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Indapta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Indapta Therapeutics \/ Sanofi","highestDevelopmentStatusID":"6","companyTruncated":"Indapta Therapeutics \/ Sanofi"},{"orgOrder":0,"company":"Indapta Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Series A Financing","leadProduct":"G-NK Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Indapta Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Indapta Therapeutics \/ RA Capital Management","highestDevelopmentStatusID":"4","companyTruncated":"Indapta Therapeutics \/ RA Capital Management"},{"orgOrder":0,"company":"Indapta Therapeutics","sponsor":"Leaps by Bayer","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Series A Financing","leadProduct":"IDP-023","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Indapta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Indapta Therapeutics \/ Leaps by Bayer","highestDevelopmentStatusID":"7","companyTruncated":"Indapta Therapeutics \/ Leaps by Bayer"},{"orgOrder":0,"company":"Indapta Therapeutics","sponsor":"CPRIT","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Funding","leadProduct":"Cyclophosphamide","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Indapta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Indapta Therapeutics \/ CPRIT","highestDevelopmentStatusID":"7","companyTruncated":"Indapta Therapeutics \/ CPRIT"},{"orgOrder":0,"company":"Indapta Therapeutics","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Collaboration","leadProduct":"IDP-023","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Indapta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Indapta Therapeutics \/ Sanofi","highestDevelopmentStatusID":"6","companyTruncated":"Indapta Therapeutics \/ Sanofi"},{"orgOrder":0,"company":"Indapta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Indapta Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Indapta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Indapta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Indapta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Indapta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Indapta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Indapta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Indapta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Indapta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Indapta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Indapta Therapeutics \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals by Indapta Therapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details : The financing will hep the company to advance the clinical development of IDP-023, which is being evaluated in the early-stage clinical trial studies for the treatment of multiple myeloma.

                          Product Name : IDP-023

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          December 17, 2024

                          Lead Product(s) : IDP-023,Cyclophosphamide

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : RA Capital Management

                          Deal Size : $22.5 million

                          Deal Type : Financing

                          blank

                          02

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details : IDP-023 is a natural killer (NK) cell therapy which is currently being investigated in phase 1/2 clinical studies for the treatment of multiple myeloma and Non-Hodgkin’s lymphoma.

                          Product Name : IDP-023

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Inapplicable

                          November 01, 2024

                          Lead Product(s) : IDP-023,Cyclophosphamide

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details : The collaboration will help Indapta to amend its ongoing phase 1 study of IDP-023, to add a cohort of IDP-023 in combination with Sarclisa for patients with relapsed/refractory multiple myeloma.

                          Product Name : IDP-023

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          June 12, 2024

                          Lead Product(s) : IDP-023,Isatuximab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Sanofi

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          04

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details : #N/A

                          Product Name : IDP-023

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          June 12, 2024

                          Lead Product(s) : IDP-023,Isatuximab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Sanofi

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          05

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details : The grant will support Indapta’s ongoing clinical development of its lead product, IDP-023, for patients with advanced non-Hodgkin’s lymphoma and multiple myeloma.

                          Product Name : IDP-023

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          May 21, 2024

                          Lead Product(s) : IDP-023,Cyclophosphamide

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : CPRIT

                          Deal Size : $4.5 million

                          Deal Type : Funding

                          blank

                          06

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details : IDP-023 is an allogeneic G-NK cell therapy, which is being evaluated for the treatment of patients with non-Hodgkin’s lymphoma and multiple myeloma.

                          Product Name : IDP-023

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Inapplicable

                          February 29, 2024

                          Lead Product(s) : IDP-023,Cyclophosphamide

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details : The financing will be used for the first-in-human phase 1 trial of DP-023, an Allogeneic Natural Killer (NK) Cell Therapy in patients with multiple myeloma and lymphoma.

                          Product Name : IDP-023

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          May 17, 2023

                          Lead Product(s) : IDP-023,Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Sponsor : Leaps by Bayer

                          Deal Size : $60.0 million

                          Deal Type : Series A Financing

                          blank

                          08

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details : The company will use the proceeds of the financing to grow the team and continue to advance its universal, allogeneic NK cell platform toward an Investigational New Drug Application (IND) and clinical trials.

                          Product Name : Undisclosed

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          October 02, 2022

                          Lead Product(s) : G-NK Cell

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : RA Capital Management

                          Deal Size : $50.0 million

                          Deal Type : Series A Financing

                          blank

                          09

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details : Indapta Therapeutics is developing a universal, allogeneic G-NK cell therapy designed to substantially improve the cytotoxicity of monoclonal antibody therapy in multiple cancers.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          October 28, 2020

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Undisclosed

                          Sponsor : Multiple Myeloma Research Foundation

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          10

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details : Company presented data from its G-NK cell therapy program in a poster presentation at the American Association for Cancer Research (AACR) Virtual Annual Meeting II in June.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          September 07, 2020

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank